Delivery Order SPE2DB22D3011-SPE2DB25FQ2DJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,633.52 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is set to be completed by August 1, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving as the place of performance for this federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $23,388.90 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes with a completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,600.42 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on July 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,194.60 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order, which was competitively awarded without set-aside designation, will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication commonly used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,609.13 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical product. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 30, 2025. The award was made on July 29, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $7,362.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 162 mg/0.9 mL Actemra syringes on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, fulfilled this delivery order under its...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2DJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $32,313.93 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price contract, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 blanket purchase agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military and federal healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, maintains extensive federal procurement capabilities across multiple therapeutic domains. The company's significant IDC with DLA Troop Support Medical positions it as a critical vendor for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This specific delivery order for Actemra, a specialty pharmaceutical used primarily for rheumatoid arthritis treatment, exemplifies the company's role in supplying brand-name medications and specialized healthcare commodities to federal military and veteran healthcare systems through competitively awarded contracts with fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.3k | 8/7/25 |